Treatment of resistant hypertension

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Although the true prevalence of resistant hypertension is not known, it is likely that this condition will become increasingly common, driven by an aging population, obesity, nonadherence trends, and effects of target-organ disease. Current approaches focus on two goals: evaluation and correction of contributing causes, then selection of an effective drug regimen. Lifestyle factors contribute to resistance, particularly high sodium intake and weight gain. Secondary causes should be considered and corrected if feasible. Recent efforts have focused on the development of clinical pathways to guide treatment, based on plasma renin activity, aldosterone production, or hemodynamic measurements. The components of drug combinations beyond the second agent remain empiric. Although volume expansion plays a key role in drug resistance, clinical assessment of volume status is often difficult, frustrating efforts to achieve blood pressure control. Determination of the most effecidve approaches will require clinical trials using combination therapy.

Original languageEnglish (US)
Pages (from-to)323-329
Number of pages7
JournalCurrent Hypertension Reports
Volume7
Issue number5
StatePublished - Oct 2005

Fingerprint

Critical Pathways
Drug Combinations
Aldosterone
Drug Resistance
Renin
Weight Gain
Life Style
Obesity
Hemodynamics
Sodium
Clinical Trials
Blood Pressure
Hypertension
Pharmaceutical Preparations
Population
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Treatment of resistant hypertension. / Taler, Sandra J.

In: Current Hypertension Reports, Vol. 7, No. 5, 10.2005, p. 323-329.

Research output: Contribution to journalArticle

@article{87cdca32c15244f88283e2d89d7e8f81,
title = "Treatment of resistant hypertension",
abstract = "Although the true prevalence of resistant hypertension is not known, it is likely that this condition will become increasingly common, driven by an aging population, obesity, nonadherence trends, and effects of target-organ disease. Current approaches focus on two goals: evaluation and correction of contributing causes, then selection of an effective drug regimen. Lifestyle factors contribute to resistance, particularly high sodium intake and weight gain. Secondary causes should be considered and corrected if feasible. Recent efforts have focused on the development of clinical pathways to guide treatment, based on plasma renin activity, aldosterone production, or hemodynamic measurements. The components of drug combinations beyond the second agent remain empiric. Although volume expansion plays a key role in drug resistance, clinical assessment of volume status is often difficult, frustrating efforts to achieve blood pressure control. Determination of the most effecidve approaches will require clinical trials using combination therapy.",
author = "Taler, {Sandra J}",
year = "2005",
month = "10",
language = "English (US)",
volume = "7",
pages = "323--329",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Treatment of resistant hypertension

AU - Taler, Sandra J

PY - 2005/10

Y1 - 2005/10

N2 - Although the true prevalence of resistant hypertension is not known, it is likely that this condition will become increasingly common, driven by an aging population, obesity, nonadherence trends, and effects of target-organ disease. Current approaches focus on two goals: evaluation and correction of contributing causes, then selection of an effective drug regimen. Lifestyle factors contribute to resistance, particularly high sodium intake and weight gain. Secondary causes should be considered and corrected if feasible. Recent efforts have focused on the development of clinical pathways to guide treatment, based on plasma renin activity, aldosterone production, or hemodynamic measurements. The components of drug combinations beyond the second agent remain empiric. Although volume expansion plays a key role in drug resistance, clinical assessment of volume status is often difficult, frustrating efforts to achieve blood pressure control. Determination of the most effecidve approaches will require clinical trials using combination therapy.

AB - Although the true prevalence of resistant hypertension is not known, it is likely that this condition will become increasingly common, driven by an aging population, obesity, nonadherence trends, and effects of target-organ disease. Current approaches focus on two goals: evaluation and correction of contributing causes, then selection of an effective drug regimen. Lifestyle factors contribute to resistance, particularly high sodium intake and weight gain. Secondary causes should be considered and corrected if feasible. Recent efforts have focused on the development of clinical pathways to guide treatment, based on plasma renin activity, aldosterone production, or hemodynamic measurements. The components of drug combinations beyond the second agent remain empiric. Although volume expansion plays a key role in drug resistance, clinical assessment of volume status is often difficult, frustrating efforts to achieve blood pressure control. Determination of the most effecidve approaches will require clinical trials using combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=27544498604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544498604&partnerID=8YFLogxK

M3 - Article

C2 - 16157072

AN - SCOPUS:27544498604

VL - 7

SP - 323

EP - 329

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 5

ER -